Leah DiMascio

1.1k total citations · 1 hit paper
11 papers, 896 citations indexed

About

Leah DiMascio is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Hematology. According to data from OpenAlex, Leah DiMascio has authored 11 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Hematology. Recurrent topics in Leah DiMascio's work include Cancer Immunotherapy and Biomarkers (5 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Leah DiMascio is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Leah DiMascio collaborates with scholars based in United States and Singapore. Leah DiMascio's co-authors include Tannishtha Reya, Andrew W. Duncan, Kendra L. Congdon, Chen Zhao, Keejung Yoon, Karl Willert, Jennifer M. Cook, Nicholas Gaiano, Carlijn Voermans and Uma Sankar and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Immunology.

In The Last Decade

Leah DiMascio

11 papers receiving 882 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance

2005 603 citations Andrew W. Duncan, Leah DiMascio et al. Nature Immunology profile →

Peers

Countries citing papers authored by Leah DiMascio

Since Specialization

Citations

This map shows the geographic impact of Leah DiMascio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leah DiMascio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leah DiMascio more than expected).

Fields of papers citing papers by Leah DiMascio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leah DiMascio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leah DiMascio. The network helps show where Leah DiMascio may publish in the future.

Co-authorship network of co-authors of Leah DiMascio

This figure shows the co-authorship network connecting the top 25 collaborators of Leah DiMascio. A scholar is included among the top collaborators of Leah DiMascio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leah DiMascio. Leah DiMascio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors. 2023 ·Journal of Clinical Oncology ·Jordi Rodón, Joshua J. Gruber, Melinda L. Telli, Monica Mita, Alain C. Mita, Joseph W. Kim, Miguel A. Villalona‐Calero, Meera Patel, Shalini S. Yadav, Padmanee Sharma, Tom Haber, (unknown), (unknown), Bhushan Dharmadhikari, Dipti Thakkar, (unknown), Leah DiMascio, Eric K. Rowinsky, Piers J. Ingram, Jerome D. Boyd‐Kirkup	6
2	Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner 2022 ·Journal for ImmunoTherapy of Cancer ·Dipti Thakkar, (unknown), Bhushan Dharmadhikari, Siyu Guan, (unknown), Shreya Kar, Nikhil Kumar Tulsian, Joshua J. Gruber, Leah DiMascio, Konrad Paszkiewicz, Piers J. Ingram, Jerome D. Boyd‐Kirkup	46
3	623 Trial in progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies 2022 ·Regular and Young Investigator Award Abstracts ·Tom Haber, (unknown), Bhushan Dharmadhikari, Thomas Müller, Dipti Thakkar, (unknown), Joshua J. Gruber, Melinda L. Telli, Monica Mita, Alain C. Mita, Meera Patel, Daniel Wang, Joseph Kim, Shalini S. Yadav, Padmanee Sharma, Leah DiMascio, Eric K. Rowinsky, Piers J. Ingram, Jerome D. Boyd‐Kirkup	2
4	A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer 2021 ·Investigational New Drugs ·Corinne Maurice‐Dror, Ronan Le Moigne, Ulka N. Vaishampayan, Bruce Montgomery, Michael S. Gordon, Nan Hyung Hong, Leah DiMascio, Frank Perabo, Kim N.	23
5	HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab. 2021 ·Journal of Clinical Oncology ·Leah DiMascio, Dipti Thakkar, Namita Gandhi, Siyu Guan, Eric K. Rowinsky, Piers J. Ingram, Jerome D. Boyd‐Kirkup	7
6	469 A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies 2021 ·Regular and Young Investigator Award Abstracts ·Leah DiMascio, Dipti Thakkar, Siyu Guan, Eric K. Rowinsky, Jordi Rodón, Joshua J. Gruber, Benjamin Musher, Joseph Kim, Alain C. Mita, Monica Mita, Piers J. Ingram, Jerome D. Boyd‐Kirkup	3
7	Gfer inhibits Jab1-mediated degradation of p27^kip1to restrict proliferation of hematopoietic stem cells 2011 ·Molecular Biology of the Cell ·(unknown), (unknown), Thomas J. Ribar, William Lento, Leah DiMascio, Anthony R. Means, Uma Sankar	11
8	Activation of Wnt Signaling in Hematopoietic Regeneration 2008 ·Stem Cells ·Kendra L. Congdon, Carlijn Voermans, (unknown), Leah DiMascio, (unknown), Chen Zhao, Tannishtha Reya	43
9	Identification of Adiponectin as a Novel Hemopoietic Stem Cell Growth Factor 2007 ·The Journal of Immunology ·Leah DiMascio, Carlijn Voermans, (unknown), Andrew W. Duncan, Danhong Lu, Judy Wu, Uma Sankar, Tannishtha Reya	151
10	Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance breakdown → 2005 ·Nature Immunology ·Andrew W. Duncan, (unknown), Leah DiMascio, Kendra L. Congdon, (unknown), Chen Zhao, Keejung Yoon, Jennifer M. Cook, Karl Willert, Nicholas Gaiano, Tannishtha Reya	603
11	Identification of Novel Regulators of Hematopoietic Stem Cell Mobilization. 2005 ·Blood ·Carlijn Voermans, William Lento, (unknown), Leah DiMascio, (unknown), (unknown), Tannishtha Reya	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact